Stocks and Investing
Stocks and Investing
Thu, August 10, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Vamil Divan Maintained (ANIP) at Strong Buy with Increased Target to $72 on, Aug 10th, 2023
Vamil Divan of Guggenheim, Maintained "ANI Pharmaceuticals, Inc." (ANIP) at Strong Buy with Increased Target from $62 to $72 on, Aug 10th, 2023.
Vamil has made no other calls on ANIP in the last 4 months.
There are 3 other peers that have a rating on ANIP. Out of the 3 peers that are also analyzing ANIP, 0 agree with Vamil's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Vamil
- Gregory Fraser of "Truist Securities" Maintained at Strong Buy with Increased Target to $60 on, Friday, July 21st, 2023
- Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $60 on, Tuesday, May 9th, 2023
- Elliot Wilbur of "Raymond James" Maintained at Buy with Increased Target to $49 on, Tuesday, May 9th, 2023
Contributing Sources